ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PRISM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03667222
Recruitment Status : Recruiting
First Posted : September 12, 2018
Last Update Posted : October 24, 2018
Sponsor:
Information provided by (Responsible Party):
BioPharmX, Inc.

Brief Summary:
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Condition or disease Intervention/treatment Phase
Papulopustular Rosacea Drug: minocycline topical gel Drug: topical gel vehicle Phase 2

Detailed Description:

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Subjects will apply approximately 1 gram of topical gel once each day for a 12 week duration. They will come to the study site at Screening, Baseline, and Weeks 4, 8, and 12 or early termination (ET) for the protocol required efficacy and safety evaluations.

At each visit, efficacy will be assessed by rosacea lesion counts, IGA, PGI-S, PGI-I, CGI-S, CGI-I, RosaQoL, Erythema Assessment Scale, Telangiectasia Assessment Scale and subject satisfaction questionnaire.

Safety will be assessed with vital signs, physical examination, laboratory tests such as clinical hematology and chemistries, investigators' and subjects' assessments of cutaneous tolerability, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and incidence of TEAEs. Blood samples will be collected to evaluate the level of minocycline in plasma at Baseline and Week 12/ET.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 176 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Vehicle control is identical to the active product in appearance
Primary Purpose: Treatment
Official Title: PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea
Actual Study Start Date : September 18, 2018
Estimated Primary Completion Date : May 17, 2019
Estimated Study Completion Date : August 17, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rosacea

Arm Intervention/treatment
Experimental: BPX-04 Active
BPX-04 1% minocycline topical gel
Drug: minocycline topical gel
Once daily administration of BPX-04 minocycline gel for 12 weeks

Placebo Comparator: BPX-04 Vehicle
BPX-04 topical gel vehicle
Drug: topical gel vehicle
Once daily administration of BPX-04 gel vehicle for 12 weeks




Primary Outcome Measures :
  1. Inflammatory lesion count [ Time Frame: Baseline to Week 12 ]
    Change in mean facial inflammatory lesion count


Secondary Outcome Measures :
  1. Change in IGA [ Time Frame: Baseline to Week 12 ]
    Proportion of subjects with ≥2-point change in IGA of rosacea to clear or almost clear



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female subjects ≥18 years of age at the time of consent.
  2. Subjects do not have any medical conditions, other than rosacea, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.
  3. A clinical diagnosis of moderate to severe (Grade 3 or 4) facial rosacea (papulopustular (Subtype 2) or mixed erythematotelangiectatic (Subtype 1) and papulopustular (Subtype 2)) as determined by the Investigator's Global Assessment (IGA)
  4. Have 15-70 papulopustular lesions of rosacea on the face with no more than 2 nodules.
  5. Female subjects of childbearing potential are willing to use effective contraceptive method (s) for at least 4 weeks before Baseline and at least 4 weeks after the last study product administration or have a sterilized or same sex partner for the duration of the study. Effective contraceptive methods are: systemic hormonal contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicide or agree to sexual abstinence. Hormonal contraceptives must be on a stable dose for at least 12 weeks before Baseline. Subjects using low dose (≤35 ug ethinyl estradiol) oral contraceptives must use a second form of birth control (e.g., barrier method such as condoms with spermicide).
  6. Female subjects of childbearing potential must have a negative urine pregnancy test (dipstick).
  7. Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 2 weeks prior to Baseline, must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the scheduled clinic visit days before the visit.
  8. Be willing to limit or avoid known personal 'triggers' of rosacea such as spicy foods, consumption of alcoholic beverages, extended sun exposure, tanning beds, etc., for the duration of the study.
  9. Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures.

Exclusion Criteria:

  1. Have a history of skin disease, presence of skin condition, scarring or excessive facial hair the PI believes would interfere with the study.
  2. Have moderate or severe rhinophyma, severe telangiectasia or plaque-like facial edema.
  3. Have rosacea conglobata or fulminans, corticosteroid induced rosacea or facial erythrosis other than rosacea.
  4. Have ocular rosacea of a severity that requires systemic treatment.
  5. Have a history of any adverse reaction to minocycline or other tetracycline class antibiotic.
  6. Have a clinically significant chemistry or hematology value or have an ALT or AST that is greater than or equal to 2x normal.
  7. Have any conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results.
  8. Have a history of symptoms that might be confused with a diagnosis of pseudotumor cerebri such as severe headaches or visual disturbances inconsistent with a diagnosis of migraine or have a history of traumatic brain injury with headache and/or visual disturbances.
  9. Have used on the face an over the counter (OTC) topical medication for the treatment of rosacea within 4 weeks prior to Baseline.
  10. Have used prescription topical (on the face) and/or oral antibiotics within 4 weeks prior to Baseline.
  11. Treatment with hormonal therapy or oral corticosteroids that is not on a stable dose and frequency for at least 12 weeks before Baseline and not stable throughout the study.
  12. Have had a facial procedure such as chemical peel, laser, microdermabrasion or injections with a dermal filler or neuromodulator within 8 weeks prior to Baseline.
  13. Have received photodynamic therapy or phototherapy to the face within 12 weeks prior to Baseline.
  14. Have used an oral retinoid within 6 months or a topical retinoid within 3 months prior to Baseline.
  15. Current drug or alcohol abuse.
  16. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.
  17. Participated in any clinical study with exposure to any investigational treatment or product within the previous 4 weeks to Baseline, or plan on concurrent participation in other studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03667222


Contacts
Contact: AnnaMarie Daniels 310-701-2080 amdaniels@biopharmx.com

Locations
United States, California
Study Center Recruiting
Anaheim Hills, California, United States, 92807
United States, Florida
Study Center Recruiting
Miami, Florida, United States, 33175
Study Center Recruiting
Miramar, Florida, United States, 33027
United States, Louisiana
Study Center Recruiting
New Orleans, Louisiana, United States, 70115
United States, Massachusetts
Study Center Recruiting
Needham, Massachusetts, United States, 02135
United States, Missouri
Study Center Recruiting
Saint Joseph, Missouri, United States, 64506
United States, North Carolina
Study Center Recruiting
High Point, North Carolina, United States, 27262
United States, Pennsylvania
Study Center Recruiting
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
Study Center Recruiting
Austin, Texas, United States, 78759
Study Center Recruiting
San Antonio, Texas, United States, 78213
Sponsors and Collaborators
BioPharmX, Inc.
Investigators
Study Director: AnnaMarie Daniels BioPharmX, Inc.

Responsible Party: BioPharmX, Inc.
ClinicalTrials.gov Identifier: NCT03667222     History of Changes
Other Study ID Numbers: BPX-04-C07
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: October 24, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Rosacea
Skin Diseases
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents